Targeting of CD8+T cells to TAAs leading to melanocytes destruction (evidenced as vitiligo) has been reported as an indicator of antitumor immune responses in CM patients that received various types of immunotherapies (31, 32). Here, CD8A is linked to cutaneous mastocytosis.